Delivery Order SPE2DB24D2205-SPE2DB25FEGKG
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $2,409.96 to AmerisourceBergen Drug Corp for Monovisc 88 mg/4 ml syringes on August 11, 2025, with an ultimate completion date of August 12, 2025. This firm fixed price, non-set-aside contract represents a single delivery order fulfillment under AmerisourceBergen's larger indefinite delivery vehicle with DLA. The pharmaceutical distributor, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office...
- The Defense Logistics Agency (DLA) awarded a $10,158.47 delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of Monovisc 88 mg/4 mL syringes. This is a firm fixed-price, competitively awarded contract with no set-aside designation, with performance scheduled for completion by July 29, 2025. The product will be delivered to the Conshohocken, Pennsylvania location, where AmerisourceBergen maintains its corporate headquarters. This delivery order is a child contract issued...
- The Defense Logistics Agency awarded a delivery order valued at $3,757.37 to AmerisourceBergen Drug Corp on July 29, 2025, for the supply of Monovisc 88 mg/4 mL syringes. The order, which represents a child contract under a larger indefinite delivery vehicle, is scheduled for completion by July 30, 2025, and will be performed at the awardee's corporate office location in Conshohocken, Pennsylvania. This award was made on a firm fixed-price basis with no set-aside designation, indicating it was...
- The Defense Logistics Agency awarded a $5,388.87 delivery order to AmerisourceBergen Drug Corp for the supply of MONOVISC 88 mg/4 ml syringes (4 ml quantity) under a firm fixed price contract type. The award, issued on July 23, 2025, with an ultimate completion date of July 24, 2025, represents a non-set-aside, competitively awarded procurement. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform this delivery order at its corporate office location in...
- The Defense Logistics Agency awarded a $8,318.78 delivery order to AmerisourceBergen Drug Corp for MONOVISC 88 mg/4 mL syringes (4 mL quantity) on July 21, 2025, with an ultimate completion date of July 22, 2025. This non-set-aside, competitively awarded contract features firm fixed pricing and represents a routine pharmaceutical supply delivery. The place of performance is located in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. This delivery order is...
- The U.S. Defense Logistics Agency (DLA) awarded a firm fixed price delivery order contract worth $1,227.19 to AmerisourceBergen Drug Corp, a subsidiary of AmerisourceBergen Corporation. This delivery order is for the supply of MONOVISC 88 MG/4 ML SYRINGE 4ML, a pharmaceutical product. The delivery order has a period of performance through March 12, 2024. AmerisourceBergen Drug Corp holds an indefinite delivery contract (IDC) awarded by DLA, valued at up to $999,999,999.00 with a performance...
- The Defense Logistics Agency (DLA) awarded Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, a firm fixed price delivery order contract worth $4,647.12 to provide MONOVISC 88 MG/4 ML SYRINGE 4ML medical supplies. This delivery order was issued under Amerisourcebergen Drug Corp's existing indefinite delivery contract (IDC) with DLA, valued at up to $999,999,999.00, that serves as the primary vehicle for the company to deliver pharmaceutical products and medical...
- The Defense Logistics Agency awarded a delivery order valued at $9,013.11 to AmerisourceBergen Drug Corp on August 5, 2025, for the supply of Monovisc 88 mg/4 ml syringes. The contract is a firm fixed-price delivery order with a completion date of August 6, 2025, and will be performed at the contractor's location in Conshohocken, Pennsylvania. This award was made through open competition with no set-aside designation, reflecting AmerisourceBergen's capability to compete for federal medical...
- AmerisourceBergen Drug Corp was awarded a $3,443.09 delivery order by the Defense Logistics Agency (DLA) on August 15, 2025, for the supply of Monovisc 88 mg/4 mL syringes. The contract is a firm fixed price delivery order with an ultimate completion date of August 18, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. This award represents a non-set-aside, competitively awarded contract, reflecting AmerisourceBergen's demonstrated capability to meet...
- The U.S. Defense Logistics Agency (DLA) awarded a $5,268.40 firm fixed-price delivery order to Amerisourcebergen Drug Corporation's Corporate Office Division for the supply of 4,565,285,746 units of the MONOVISC 88 MG/4 ML SYRINGE 4ML medical product. This delivery order was issued under a larger Indefinite Delivery Contract (IDC) valued up to $999,999,999 that Amerisourcebergen holds with the DLA Troop Support Medical, which provides a comprehensive range of pharmaceutical and medical...
- SPE2DB24D2205Indefinite Delivery Contract
- SPE2DB24D2205-SPE2DB25FEGKGDelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $12,453.60 to AmerisourceBergen Drug Corp for the supply of Monovisc 88 mg/4 mL syringes on August 18, 2025, with an ultimate completion date of August 19, 2025. This delivery order, issued on a firm fixed-price basis with no set-aside designation, represents a competitive award for pharmaceutical supplies to support federal medical procurement needs. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a comprehensive global pharmaceutical support vehicle valued at $999.99 million and running through December 2026. This prime contract enables AmerisourceBergen to supply a broad range of pharmaceutical products and medical supplies, including specialty medications, brand-name and generic drugs, vaccines, and medical devices to support military healthcare systems worldwide. The DLA Troop Support Medical program serves critical customers including the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems, with plans to establish next-generation Pharmaceutical Prime Vendor Global Program contracts involving multiple regional awards.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $12.5k | 8/18/25 |